Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports

The Firm is representing numerous Risperdal lawsuit plaintiffs who have filed cases in Pennsylvania that allege the drug caused gynecomastia (male breast growth).

New York, New York (PRWEB) September 21, 2014

Hundreds of Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) continue to move forward in Pennsylvania's Philadelphia Court of Common Pleas, Bernstein Liebhard LLP reports. According to court documents, the proceeding's next monthly meeting has been scheduled for October 15, 2014. (Risperdal Litigation, case number 100300296)

“Our Firm is representing a number of plaintiffs who have filed Risperdal lawsuits in this litigation. We are pleased with its continued progress,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia, or male breast growth, due to their use of Risperdal.

Risperdal Litigation
Risperdal is an atypical antipsychotic drug that is approved by the U.S. Food & Drug Administration (FDA) to treat adult and adolescent schizophrenia, bipolar disorder in adults and children ages 10-to-17, and irritability in children (5-to-16 years of age) with autistic disorder.* Recent research indicates that off- label use of Risperdal to treat ADHD is also on the rise**

Court records indicate that more than 700 Risperdal lawsuits have been filed in the Pennsylvania litigation on behalf of individuals who suffered gynecomastia and other serious side effects allegedly associated with use of the medication. Cases that involve male breast growth further allege that Risperdal can cause the body to produce excessive amounts of prolactin, a hormone which is known to stimulate breast growth and milk production in women, as well as the development of excess breast tissue in men and boys. Among other things, Johnson & Johnson and its Janssen Pharmaceuticals unit are accused of concealing the link between Risperdal and gynecomastia, and of improperly marketing the medication for off-label pediatric uses.

Last November, Johnson & Johnson and Janssen agreed to pay $2.2 billion to settle allegations brought against them by the U.S. Department of Justice over the marketing of Risperdal and other medications. Among other things, the government had charged the companies with improperly marketing Risperdal for use in children before pediatric indications were approved in 2006, and further alleged that they had concealed the serious side effects linked to its use. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)

Men and boys who allegedly developed gynecomastia from Risperdal may be entitled to compensation for medical bills, lost wages, pain and suffering and more. Learn more about filing a Risperdal lawsuit by visiting Bernstein Liebhard LLP's website. Free case reviews may also be obtained by calling the Firm directly at 800-511-5092.

*http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s03lbl.pdf, Risperdal Prescribing Information, FDA, 2009
**health.usnews.com/health-news/news/articles/2012/08/07/more-kids-taking-antipsychotics-for-adhd-study, U.S. News & World Report, August 7, 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com
http://www.risperdallawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author

For the original version on PRWeb visit: http://www.prweb.com/releases/risperdal-lawsuit/risperdal-gynecomastia/prweb12186039.htm